Abstract
Solution-phase synthesis and a solid-phase supported approach to piperazinylmethyl substituted pyrroles are described. Receptor binding studies and the measurement of D4 ligand efficacy led to the ethynylpyrrole 1d (FAUC 356) exerting selective D4 binding and substantial ligand efficacy (66%, EC(50)=1.9nM). This activity profile might be of interest for the treatment of ADHD.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Binding Sites
-
CHO Cells
-
Cattle
-
Cloning, Molecular
-
Cricetinae
-
Humans
-
Piperazines / chemical synthesis*
-
Piperazines / chemistry
-
Piperazines / pharmacology*
-
Protein Binding
-
Pyrroles / chemical synthesis*
-
Pyrroles / chemistry*
-
Pyrroles / pharmacology*
-
Radioligand Assay
-
Receptors, Dopamine / metabolism
-
Receptors, Dopamine D2 / agonists*
-
Receptors, Dopamine D2 / metabolism
-
Receptors, Dopamine D4
-
Receptors, Serotonin / metabolism
-
Structure-Activity Relationship
-
Substrate Specificity
-
Swine
Substances
-
DRD4 protein, human
-
FAUC 356
-
Piperazines
-
Pyrroles
-
Receptors, Dopamine
-
Receptors, Dopamine D2
-
Receptors, Serotonin
-
Receptors, Dopamine D4